Published in BMJ on April 26, 2011
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med (2016) 1.40
Symmetrical analysis of risk-benefit. Br J Clin Pharmacol (2012) 1.02
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail (2013) 1.02
Newer is not always better: all antihypertensive medications do not equally reduce cardiovascular risk. J Gen Intern Med (2012) 0.94
Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence. Am J Cardiovasc Drugs (2014) 0.82
Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol (2014) 0.82
The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf (2015) 0.80
Activation of the ACE2/Ang-(1-7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction. Neuroscience (2014) 0.79
RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract (2013) 0.78
Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril. Vasc Health Risk Manag (2014) 0.78
Angiotensin receptor blockers and cardiovascular outcomes. BMJ (2011) 0.77
Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord (2014) 0.77
The "ARB-MI paradox": real or a fluke? Am Fam Physician (2012) 0.75
Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand? Open Heart (2015) 0.75
Analyzing Dynamic Changes of Laboratory Indexes in Patients with Acute Heart Failure Based on Retrospective Study. Biomed Res Int (2016) 0.75
ACP Journal Club. Review: angiotensin-receptor blockers do not increase adverse cardiovascular outcomes. Ann Intern Med (2011) 0.75
Postrandomization Confounding Challenges the Applicability of Randomized Clinical Trials in Comparative Effectiveness Research. Chin Med J (Engl) (2017) 0.75
Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study. BMC Health Serv Res (2016) 0.75
Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. J Cell Mol Med (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Interaction revisited: the difference between two estimates. BMJ (2003) 11.97
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet (1997) 7.46
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med (2004) 6.21
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Retracted Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet (2007) 5.17
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol (2007) 4.06
A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med (1988) 3.91
Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med (2009) 3.60
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 2.89
Retracted Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J (2009) 2.83
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol (2008) 2.61
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 2.49
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis (2008) 2.39
Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol (2009) 2.39
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens (2003) 2.24
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med (2009) 2.14
Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant (2006) 2.11
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol (2007) 2.09
Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 2.02
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens (2007) 2.01
Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev (1995) 1.91
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation (2010) 1.72
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol (2006) 1.71
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension (2008) 1.54
Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J (2003) 1.50
Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation (2004) 1.42
Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res (2005) 1.13
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev (2008) 1.09
Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation (2009) 0.92
An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res (2005) 0.86
Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med (2013) 20.70
Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med (2012) 10.34
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol (2008) 7.04
Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med (2014) 6.93
Obesity paradox in patients with hypertension and coronary artery disease. Am J Med (2007) 5.61
Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet (2008) 5.05
Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med (2013) 5.02
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med (2007) 4.20
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation (2011) 3.81
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (2011) 3.73
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation (2012) 3.14
A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol (2007) 3.07
Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J (2007) 2.86
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2011) 2.72
Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol (2008) 2.66
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol (2008) 2.61
Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med (2010) 2.33
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J (2010) 2.32
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol (2008) 2.31
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med (2015) 2.25
Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry (2013) 2.22
Modified Trachlight for management of difficult pediatric airway. Paediatr Anaesth (2008) 2.19
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev (2013) 2.18
Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) (2012) 2.16
Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. Cleve Clin J Med (2011) 2.09
High body mass index is a weak predictor for difficult and failed tracheal intubation: a cohort study of 91,332 consecutive patients scheduled for direct laryngoscopy registered in the Danish Anesthesia Database. Anesthesiology (2009) 2.06
Chest Sonography in the Diagnosis of Pneumothorax. Indian J Chest Dis Allied Sci (2015) 2.05
The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One (2011) 2.02
Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2014) 2.01
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension (2004) 1.90
Ensemble habitat mapping of invasive plant species. Risk Anal (2010) 1.86
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med (2003) 1.83
Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol (2007) 1.76
Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med (2013) 1.75
Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med (2011) 1.66
Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev (2011) 1.63
Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol (2006) 1.60
Natural history of bleeding after esophageal variceal eradication in patients with extrahepatic portal venous obstruction; a 20-year follow-up. Indian J Gastroenterol (2010) 1.52
Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol (2004) 1.52
Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol (2008) 1.52
Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens (2007) 1.51
Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate. Intensive Care Med (2014) 1.49
Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med (2014) 1.48
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST. Stroke (2007) 1.46
Antihypertensive therapy and new onset diabetes. J Hypertens (2004) 1.45
Systematic Reviews of Anesthesiologic Interventions Reported as Statistically Significant: Problems with Power, Precision, and Type 1 Error Protection. Anesth Analg (2015) 1.45
Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J Hypertens (2012) 1.45
Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol (2007) 1.44
Microclusters of inhibitory killer immunoglobulin-like receptor signaling at natural killer cell immunological synapses. J Cell Biol (2006) 1.42
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev (2011) 1.42
Evaluation of thyroid hormone levels in chronic kidney disease patients. Saudi J Kidney Dis Transpl (2015) 1.41
Authors' reply to Laragh and Sealey. BMJ (2013) 1.40
Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers. Am Heart J (2003) 1.39
Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease. Cochrane Database Syst Rev (2012) 1.39
Recurrence of herpes simplex keratitis after azithromycin. Indian J Ophthalmol (2006) 1.39
The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des (2005) 1.39
Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure. Am J Cardiol (2010) 1.38
Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One (2012) 1.33
Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke (2006) 1.33
Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol (2006) 1.32
Hypothermia after cardiac arrest should be further evaluated--a systematic review of randomised trials with meta-analysis and trial sequential analysis. Int J Cardiol (2010) 1.31
Indigenous knowledge of medicinal plants used by Saperas community of Khetawas, Jhajjar District, Haryana, India. J Ethnobiol Ethnomed (2010) 1.30
Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) (2012) 1.29
GABA-mediated control of hypocretin- but not melanin-concentrating hormone-immunoreactive neurones during sleep in rats. J Physiol (2004) 1.28
Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol (2006) 1.26
Imaging features of central nervous system fungal infections. Neurol India (2007) 1.26
Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil (2010) 1.25
Beyond salt: lifestyle modifications and blood pressure. Eur Heart J (2011) 1.24
Multiplexed FRET to image multiple signaling events in live cells. Biophys J (2008) 1.23
Salt and hypertension: is salt dietary reduction worth the effort? Am J Med (2012) 1.22
Trials on stress ulcer prophylaxis: finding the balance between benefit and harm. Intensive Care Med (2015) 1.22
Natural killer cell signal integration balances synapse symmetry and migration. PLoS Biol (2009) 1.22
Association between sperm quality, oxidative stress, and seminal antioxidant activity. Clin Biochem (2010) 1.22
Target Temperature Management after out-of-hospital cardiac arrest--a randomized, parallel-group, assessor-blinded clinical trial--rationale and design. Am Heart J (2012) 1.22
Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol (2007) 1.21
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med (2010) 1.17
Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol (2010) 1.16
Is there an association between hypertension and cancer mortality? Am J Med (2002) 1.15